Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover

Crofton, Patricia M.; Evans, Nancy; Bath, Louise; Warner, Pamela; Whitehead, T; Critchley, Hilary O. D.; Kelnar, Christopher J. H.; Wallace, W. Hamish B.

doi:10.1111/j.1365-2265.2010.03868.x

Cited by 135 publications

(102 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is some evidence that transdermal versus oral replacement therapy in female CCS may be of advantage [51, 56]; however, this was considered insufficient to form a strong recommendation [11, 51]. Treatment with estrogen needs to be combined with progestin for endometrial cycling.…”

Section: Treatment Of Gonadal Insufficiency (Primary and Central)mentioning

confidence: 99%

See 1 more Smart Citation

Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up

et al. 2019

View full text Add to dashboard Cite

Hypogonadism after treatment for childhood cancer is a recognized complication and its cause may be subdivided into primary gonadal failure and central hypogonadism. Here, we provide an overview of the risk factors for the development of hypogonadism, assessment and potential interventions and give a summary of the current recommendations for management and follow-up of hypogonadism in childhood cancer survivors.

show abstract

Section: Treatment Of Gonadal Insufficiency (Primary and Central)mentioning

confidence: 99%

“…In postpubertal girls and women, replacement of sex steroids will positively influence bone health and cardiovascular status [51]. For all females, replacement of estrogen may influence growth of the uterus, enabling possible future (donor) pregnancy [52].…”

Section: Treatment Of Gonadal Insufficiency (Primary and Central)mentioning

confidence: 99%

Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In addition, studies of treatment acceptability and patient adherence are lacking [13]”. Thus, while transdermal estradiol may be superior to oral ethinylestradiol in terms of cardiac, bone and uterine health in POI [16-18], adequately powered studies are needed to address these as well as other elements such as growth during pubertal induction, adherence and acceptability [19]. …”

Section: Introductionmentioning

confidence: 99%

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

et al. 2019

View full text Add to dashboard Cite

Background: Most girls with Turner syndrome (TS) require pubertal induction with estrogen, followed by long term replacement. However, no adequately powered prospective studies comparing transdermal with oral 17β-estradiol administration exist. This reflects the difficulty of securing funding to study a rare condition with relatively low morbidity/mortality when competing against conditions such as cancer and vascular disease. Protocol Consensus: The TS Working Group of the European Society for Paediatric Endocrinology (ESPE) has agreed to both a 3-year oral and a 3-year transdermal regimen for pubertal induction. Prerequisites include suitable 17β-estradiol tablets and matrix patches to allow the delivery of incremental doses based on body weight. Study Proposal: An international prospective cohort study with single centre analysis is proposed in which clinicians and families are invited to choose either of the agreed regimens, usually starting at 11 years. We hypothesise that pubertal induction with transdermal estradiol will result in better outcomes for some key parameters. The primary outcome measure chosen is height gain during the induction period. Analysis: Assessment of the demographics and drop-out rates of patients choosing either oral or transdermal preparations; and appropriate analysis of outcomes including pubertal height gain, final height, liver enzyme and lipid profile, adherence/acceptability, cardiovascular health, including systolic and diastolic blood pressure and aortic root diameter and bone health. Conclusion: The proposed model of prospective data collection according to internationally agreed protocols aims to break the current impasse in obtaining evidence-based management for TS and could be applied to other rare paediatric endocrine conditions.

show abstract

“…Contudo, a densidade mineral óssea (DMO) da coluna lombar melhorou em ambos os grupos. É incerto se a administração de doses fisiológicas de estrogênio seguida por uma progestina é melhor para a saúde do esqueleto do que doses farmacológicas de um regime de estrogênio-progestina combinado (ou seja, os contraceptivos orais) (43).…”

Section: Manutenção Da Saúde óSseaunclassified

Falência ovariana precoce

Assumpção

2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOEste artigo irá rever os diversos aspectos da falência ovariana prematura (FOP), definida como o desenvolvimento de hipogonadismo em mulheres antes dos 40 anos, desde a etiopatogenia, com discussões sobre as causas autoimunes, iatrogênicas, ou anormalidades do cromossomo X assim como manifestações clínicas, diagnóstico e tratamento. A maioria das mulheres com essa condição não possui uma história menstrual, específica do desenvolvimento da FOP, mas a infertilidade associada ao diagnóstico é o aspecto mais problemático da doença. INTRODUÇÃO M uitas revisões recentes têm discutido o nome apropriado para essa condição, embora muitos pacientes e médicos prefiram o termo menopausa prematura, um termo simples e compreensível que pode ser explicado aos amigos e familiares, mas implica certa sensação de permanência, no entanto, a ovulação e a gravidez podem ocorrer em um momento posterior, por vezes anos após o diagnóstico (1-3).A falência ovariana precoce (FOP) é definida como falência gonadal antes dos 40 anos de idade. A incidência é de aproximadamente 1 em 250 mulheres com idade de 35 anos e de 1 em 100 com idade de 40 anos. É idiopática em 74% a 90% das pacientes. Algumas pacientes com FOP podem produzir estrogênio, ovular, e, em 5% a 10% dos casos, conceber e ter uma gravidez e parto sem alterações, assim como ter a função ovariana intermitente (sem amenorreia associada) e menstruação espontânea (embora anormalidades da função menstrual estejam presentes) (3-9).Neste artigo, o termo a ser utilizado será falência ovariana precoce (FOP), o qual é adequado e descreve seu diagnóstico. ETIOLOGIA E PATOGENIAEntender a causa da FOP exige uma compreensão do processo de foliculogênese em que muitas das molé-culas que regulam a série de eventos na maturação folicular estão envolvidas. O processo de maturação folicular ocorre de forma contínua e pode demorar até um ano para proceder o início do crescimento de um folículo primordial até se tornar um folículo ovulatório. A granulosa e as células somáticas da teca sintetizam e secretam fatores de crescimento e diferenciação, fatores de transcrição, como o FOXL2, inibina e hormônios esteroides que são regulados pelas http://dx

show abstract

Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover

Abstract: The aim of this exploratory study was to establish whether we could improve skeletal health with a physiological regimen of SSR in young women with premature ovarian failure (POF).

Cited by 135 publications

References 29 publications

Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up

Hypogonadism in Children with a Previous History of Cancer: Endocrine Management and Follow-Up

Optimal Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy

Falência ovariana precoce

Contact Info

Product

Resources

About